288 related articles for article (PubMed ID: 24788619)
41. Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study.
Kuijper TM; Luime JJ; Xiong H; de Jong P; van der Lubbe P; van Zeben D; Tchetverikov I; Hazes J; Weel A
Scand J Rheumatol; 2018 May; 47(3):178-184. PubMed ID: 28967272
[TBL] [Abstract][Full Text] [Related]
42. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
43. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
[TBL] [Abstract][Full Text] [Related]
44. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
45. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
46. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
47. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
Saevarsdottir S; Rezaei H; Geborek P; Petersson I; Ernestam S; Albertsson K; Forslind K; van Vollenhoven RF;
Ann Rheum Dis; 2015 Aug; 74(8):1509-14. PubMed ID: 24706006
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
Ann Rheum Dis; 2015 Jun; 74(6):1094-101. PubMed ID: 24737786
[TBL] [Abstract][Full Text] [Related]
49. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
[TBL] [Abstract][Full Text] [Related]
50. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
[TBL] [Abstract][Full Text] [Related]
51. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
Navarro-Millán I; Charles-Schoeman C; Yang S; Bathon JM; Bridges SL; Chen L; Cofield SS; Dell'Italia LJ; Moreland LW; O'Dell JR; Paulus HE; Curtis JR
Arthritis Rheum; 2013 Jun; 65(6):1430-8. PubMed ID: 23460074
[TBL] [Abstract][Full Text] [Related]
52. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
53. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs.
Dale J; Alcorn N; Capell H; Madhok R
Nat Clin Pract Rheumatol; 2007 Aug; 3(8):450-8; quiz, following 478. PubMed ID: 17664952
[TBL] [Abstract][Full Text] [Related]
54. Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy: A Swedish Nationwide Register Study.
Källmark H; Einarsson JT; Nilsson JÅ; Olofsson T; Saxne T; Geborek P; C Kapetanovic M
Arthritis Rheumatol; 2021 Jul; 73(7):1135-1144. PubMed ID: 33682353
[TBL] [Abstract][Full Text] [Related]
55. Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.
Kuusalo LA; Puolakka KT; Kautiainen H; Alasaarela EM; Hannonen PJ; Julkunen HA; Kaipiainen-Seppänen OA; Korpela MM; Möttönen TT; Paimela LH; Peltomaa RL; Yli-Kerttula TK; Leirisalo-Repo M; Rantalaiho VM;
Clin Exp Rheumatol; 2016; 34(6):1038-1044. PubMed ID: 27494516
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P;
Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568
[TBL] [Abstract][Full Text] [Related]
57. Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.
Rantalaiho VM; Kautiainen H; Korpela M; Hannonen PJ; Leirisalo-Repo M; Möttönen T;
Ann Rheum Dis; 2013 May; 72(5):786-8. PubMed ID: 23349132
[No Abstract] [Full Text] [Related]
58. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study.
Maillefert JF; Combe B; Goupille P; Cantagrel A; Dougados M
Ann Rheum Dis; 2003 Aug; 62(8):764-6. PubMed ID: 12860733
[TBL] [Abstract][Full Text] [Related]
59. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
60. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF; Geborek P; Forslind K; Albertsson K; Ernestam S; Petersson IF; Chatzidionysiou K; Bratt J;
Lancet; 2012 May; 379(9827):1712-20. PubMed ID: 22464340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]